Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 BMRN The Nasdaq Global Select Market ______________________________________ Form 10-Q Commission File Number: 000-26727 ______________________________________ BioMarin Pharmaceutical Inc. (Exact name of registrant as specified in its charter) ______________________________________ Delaware 68-0397820 (State or other jurisdiction of incorpo ...

Your next question comes from the line of Paul Matteis from Stifel. Your line is now open. Paul Matteis Hey, thanks so much for taking my question. On VOXZOGO, Jeff, does the supply issue or, I guess, capacity issue temporarily impact how you market the drug? And how might that impact the way you sort of seek to interact with health care providers and patients if and when the label is expanded before the capacity constraint is fully resolved. And then on ROCTAVIAN just in terms of the timing, the 2- to 5-mo ...

| --- | --- | --- | --- | --- | --- | --- | |----------------------------------|-------------|---------------------------------------------------------------------------------------|-------|---------------------------------------------|-------|--------| | Assets: | Significant | Fair Value Measurements as of December 31, 2022 \n Other Observable Inputs (Level 2) | | Significant Unobservable Inputs (Level 3) | | Total | | Other current assets: | | | | | | | | NQDC Plan assets | $ | 2,654 | $ | — | $ | 2,654 ...

Biomarin Pharmaceutical, Inc. (NASDAQ:BMRN) Q1 2023 Earnings Conference Call April 26, 2023 4:30 PM ET Company Participants Thank you, Ross, and thank you all for joining us today. To remind you, this nonconfidential presentation contains forward-looking statements about the business prospects of BioMarin Pharmaceutical, including expectations regarding BioMarin's financial performance, commercial products and potential future products in different areas of therapeutic research and development. On the call ...

Company Participants Operator BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q4 2022 Results Conference Call February 28, 2023 4:30 PM ET Conference Call Participants Welcome to the BioMarin Fourth Quarter Investor Update Call. Hosting the conference call today from BioMarin is Traci McCarty, Group Vice President of Investor Relations. Please go ahead, Traci. Thank you, Paul, and thank you all for joining us today. Results may differ materially depending on the progress of BioMarinÂ's product programs, actions ...

We conduct a significant amount of our sales and operations outside of the U.S., which subjects us to additional business risks that could adversely affect our revenues and results of operations. • trade protection measures and import or export licensing requirements; • changes in international medical reimbursement policies and programs; Any of these factors may, individually or as a group, have a material adverse effect on our business and results of operations. For example, Russia's invasion of Ukraine a ...

Table of Contents Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 BMRN The Nasdaq Global Select Market ______________________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ Form 10-Q ______________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANG ...

Biomarin Pharmaceutical, Inc. (NASDAQ:BMRN) Q3 2022 Earnings Conference Call October 26, 2022 4:30 PM ET Company Participants Traci McCarty - VP, IR J.J. Bienaime - Chairman & CEO Jeffrey Ajer - EVP & Chief Commercial Officer Henry Fuchs - President, Worldwide Research & Development Brian Mueller - EVP, Finance & CFO Conference Call Participants Philip Nadeau - Cowen and Company Salveen Richter - Goldman Sachs Jessica Fye - JPMorgan Chase & Co. Srikripa Devarakonda - Truist Securities Paul Matteis - Stifel, ...

Table of Contents Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 BMRN The Nasdaq Global Select Market ______________________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ Form 10-Q ______________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANG ...

Call Start: 16:30 January 1, 0000 5:42 PM ET BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q2 2022 Earnings Conference Call August 3, 2022 16:30 ET Company Participants Traci McCarty - Vice President of Investor Relations J.J. Bienaime - Chairman and Chief Executive Officer Jeff Ajer - Executive Vice President and Chief Commercial Officer Hank Fuchs - President, Worldwide Research and Development Brian Mueller - Executive Vice President and Chief Financial Officer Greg Guyer - Executive Vice President and Chie ...